According to 2022 ELN guidelines, MRD monitoring in patients with NPM1-mutated AML is critical in evaluating disease response to drugs, guiding post-remission therapy and, in parallel, predicting relapse [31]. This evidence concerns the gene NPM1 and acute myeloid leukemia.